Physician profile
Robert A Redden
NPI 1770580722
$1,850.32
in general payments reported to CMS, 2019-2025
25 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $167 · 2021: $184 · 2022: $433 · 2023: $255 · 2024: $404 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $258.98 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $245.41 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $183.20 | 2019-2024 | Gardasil 9, Vaxneuvance, Verquvo |
| Abbvie INC. | $171.41 | 2022-2025 | |
| Insulet Corporation | $141.79 | 2024 | Omnipod |
| Astrazeneca Pharmaceuticals Lp | $139.52 | 2020-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $94.11 | 2022-2023 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $88.89 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $55.07 | 2019-2021 | |
| Amgen INC. | $52.75 | 2021-2023 | Otezla, Repatha |
| Pfizer INC. | $49.13 | 2021-2023 | |
| Axsome Therapeutics, INC. | $47.33 | 2024 | Auvelity |
| Allergan, INC. | $45.79 | 2019-2020 | |
| Amarin Pharma, INC. | $34.93 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.44 | 2022-2023 | Trintellix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.85 | 2019 | |
| Biogen, INC. | $25.81 | 2024 | |
| Phathom Pharmaceuticals, INC. | $23.62 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $23.55 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.87 | 2022 | |
| Coopersurgical, INC. | $19.50 | 2019 | |
| Mylan Specialty L.P. | $18.67 | 2022 | |
| Cranial Technologies, INC | $14.72 | 2020 | |
| Exact Sciences Corporation | $14.68 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $13.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Redden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.